Vir Biotechnology (VIR) Change in Receivables (2021 - 2024)
Vir Biotechnology recorded quarterly Change in Receivables of $8.7 million in Q4 2024, up 16098.15% quarter-over-quarter from $54000.0 in Q3 2024, and up 142.57% year-over-year from $3.6 million in Q1 2024.
Vir Biotechnology's Change in Receivables history runs 4 years deep, the most recent figure standing at $8.7 million for Q4 2024.
- In Q4 2024, Change in Receivables rose 142.57% year-over-year to $8.7 million; the TTM figure through Dec 2024 stood at $6.5 million (up 1052.74% YoY), while the FY2024 annual figure was $6.5 million, up 1052.74% from the prior year.
- Change in Receivables came in at $8.7 million for Q4 2024 at Vir Biotechnology, up from $54000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $680.1 million in Q4 2021 to a low of -$883.8 million in Q2 2022.
- A 4-year average of $778384.6 and a median of $54000.0 in 2024 frame the typical range for Change in Receivables.
- On a YoY basis, Change in Receivables climbed as much as 142.57% in 2024 and fell as far as 183.65% in 2024.
- Vir Biotechnology's Change in Receivables stood at $680.1 million in 2021, then sank by 140.9% to -$278.2 million in 2022, then soared by 101.3% to $3.6 million in 2023, then jumped by 142.57% to $8.7 million in 2024.
- According to Business Quant data, Change in Receivables over the past three periods registered $8.7 million, $54000.0, and -$2.7 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -1.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 110.42 Mn |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 8.75 Mn |
| Dec 31, 2024 | 8.75 Mn |
| Sep 30, 2024 | 54,000.00 |
| Sep 30, 2024 | 54,000.00 |
| Jun 30, 2024 | -2.69 Mn |
| Jun 30, 2024 | -2.69 Mn |
| Mar 31, 2024 | 401,000.00 |
| Mar 31, 2024 | 401,000.00 |
| Dec 31, 2023 | 3.61 Mn |
| Dec 31, 2023 | 3.61 Mn |
| Jun 30, 2023 | -948,000.00 |
| Jun 30, 2023 | -948,000.00 |
| Mar 31, 2023 | -2.09 Mn |
| Mar 31, 2023 | -2.09 Mn |
| Dec 31, 2022 | -278.17 Mn |
| Dec 31, 2022 | -278.17 Mn |
| Sep 30, 2022 | -58.18 Mn |
| Sep 30, 2022 | -58.18 Mn |
| Jun 30, 2022 | -883.77 Mn |
| Jun 30, 2022 | -883.77 Mn |
| Mar 31, 2022 | 450.08 Mn |
| Mar 31, 2022 | 450.08 Mn |
| Dec 31, 2021 | 680.08 Mn |
| Dec 31, 2021 | 680.08 Mn |
| Sep 30, 2021 | 93.00 Mn |
| Sep 30, 2021 | 93.00 Mn |